Butyric acid
|
Basic information |
| Metabolite name | Butyric acid |
 | HMDB0000039 |
 |
C00246 |
 |
264 |
| Synonyms | Butyrate; |
| No. of studies | 43 |
|
Basic information |
| Metabolite name | Butyric acid |
| HMDB0000039 |
|
C00246 |
|
264 |
| Synonyms | Butyrate; |
| No. of studies | 43 |
|
Relationship between Butyric acid and depression (count: 43) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M067 | Type1 | naturally-occurring depression group vs. control group | Serum | Cynomolgus monkey | Down |
| Study M1001 | Type3 | Roseburia hominis group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1002 | Type2 | high-fat diet + Faecalibaculum rodentium group vs. high-fat diet group | Faece | C57Bl6/J mouse | Up |
| Study M1002 | Type2 | high-fat diet + Xiaoyao San group vs. high-fat diet group | Faece | C57Bl6/J mouse | Up |
| Study M1003 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M1003 | Type2 | CUMS + high dose of alcohol-soluble polysaccharides group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M1003 | Type2 | CUMS + Morinda officinalis oligosaccharide group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M1004 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M1006 | Type2 | maternal separation + Bifidobacterium breve CCFM1025 group vs. maternal separation group | Faece | C57BL/6J mouse | Up |
| Study M1009 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M1009 | Type2 | CUMS + multi-probiotics group vs. CUMS group | Faece | C57BL/6 mouse | Up |
| Study M1016 | Type1 | CUMS group vs. control group | Faece | C57BL/6J mouse | Down |
| Study M1016 | Type2 | CUMS + imipramine group vs. CUMS group | Faece | C57BL/6J mouse | Up |
| Study M1016 | Type2 | CUMS + ginsenoside Rh4 group vs. CUMS group | Faece | C57BL/6J mouse | Up |
| Study M1017 | Type1 | healthy control partners pair-housed with post-stroke depression group vs. control group | Serum | C57BL/6j mouse | Down |
| Study M1025 | Type2 | CUMS + Bacillus licheniformis group vs. CUMS group | Faece | Sprague-Dawley rat | Down |
| Study M1026 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M1027 | Type1 | CUMS group vs. control group | Faece | Wistar rat | Down |
| Study M1027 | Type2 | CUMS + fluoxetine group vs. CUMS group | Faece | Wistar rat | Up |
| Study M1040 | Type2 | CUMS + Bacteroides uniformis group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M1042 | Type1 | CUMS + MCAO group vs. MCAO group | Faece | Sprague-Dawley rat | Down |
| Study M1048 | Type2 | adult high-fat diet + probiotic group vs. adult high-fat diet group | Faece | CD-1 mouse | Up |
| Study M1048 | Type3 | adult probiotic group vs. adult control group | Faece | CD-1 mouse | Up |
| Study M1086 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M1100 | Type2 | CSDS + isoalantolactone group vs. CSDS group | Faece | C57BL/6 mouse | Up |
| Study M1100 | Type2 | CSDS + fluoxetine group vs. CSDS group | Faece | C57BL/6 mouse | Up |
| Study M1127 | Type2 | flavonoid-rich orange juice group, after 8-week treatment vs. baseline | Faece | Human | Up |
| Study M1137 | Type1 | paclitaxel group vs. control group | Faece | CD1 mouse | Down |
| Study M1137 | Type2 | paclitaxel + sodium butyrate group vs. paclitaxel group | Faece | CD1 mouse | Up |
| Study M1137 | Type3 | sodium butyrate group vs. control group | Faece | CD1 mouse | Up |
| Study M536 | Type1 | naturally-occurring depression group vs. control group | Cerebrospinal fluid | Cynomolgus monkey | Up |
| Study M547 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M565 | Type1 | CUMS group vs. control group | Intestine | C57BL/6 mouse | Down |
| Study M565 | Type2 | CUMS + minocycline group vs. CUMS group | Intestine | C57BL/6 mouse | Up |
| Study M667 | Type1 | CRS group vs. control group | Faece | C57BL/6 J mouse | Down |
| Study M667 | Type2 | CRS + crocin-I group vs. CRS group | Faece | C57BL/6 J mouse | Up |
| Study M706 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M706 | Type2 | CUMS + CCFM1025 group vs. CUMS group | Faece | C57BL/6 mouse | Up |
| Study M707 | Type1 | CUMS group vs. control group | Faece | C57BL/6J mouse | Down |
| Study M707 | Type2 | CUMS + S60 group vs. CUMS group | Faece | C57BL/6J mouse | Up |
| Study M707 | Type2 | CUMS + F45BB group vs. CUMS group | Faece | C57BL/6J mouse | Up |
| Study M707 | Type2 | CUMS + E41 group vs. CUMS group | Faece | C57BL/6J mouse | Up |
| Study M708 | Type1 | CUMS group vs. control group | Faece | C57BL/6J mouse | Down |
| Study M708 | Type2 | CUMS + CCFM687 group vs. CUMS group | Faece | C57BL/6J mouse | Down |
| Study M778 | Type1 | LPS group vs. control group | Faece | C57BL/6J mouse | Down |
| Study M778 | Type2 | LPS + NU9056 group vs. LPS group | Faece | C57BL/6J mouse | Up |
| Study M804 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M804 | Type2 | CUMS + middle dose of WYJYD group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M804 | Type2 | CUMS + fluoxetine group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M804 | Type2 | CUMS + high dose of WYJYD group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M821 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M835 | Type1 | CRS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M845 | Type1 | CRS group vs. control group | Faece | Mouse | Down |
| Study M872 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M872 | Type2 | CUMS + rifaximin group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M872 | Type2 | CUMS + rifaximin group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M886 | Type1 | lead-exposed group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M886 | Type2 | lead-exposed + probiotics group vs. lead-exposed group | Faece | Sprague-Dawley rat | Up |
| Study M894 | Type2 | electromagnetic field exposure + heat acclimation group vs. electromagnetic field exposure group | Serum | C57BL/6J mouse | Down |
| Study M901 | Type1 | LPS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M901 | Type2 | LPS + Schisandrin group vs. LPS group | Faece | C57BL/6 mouse | Up |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M934 | Type1 | CUS + high-fat diet group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M934 | Type2 | CUS + high-fat diet + 5-hydroxytryptophan group vs. CUS + high-fat diet group | Serum | C57BL/6J mouse | Up |
| Study M950 | Type2 | probiotic group vs. placebo group | Faece | Human | Up |
| Study M955 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M955 | Type2 | CUMS + deoiled sunflower seeds group vs. CUMS group | Hippocampus | C57BL/6J mouse | Down |
| Study M955 | Type2 | CUMS + tryptophan-enriched whey protein-based group vs. CUMS group | Hippocampus | C57BL/6J mouse | Down |
| Study M955 | Type2 | CUMS + deoiled and dechlorogenic acid-enriched sunflower seeds group vs. CUMS group | Hippocampus | C57BL/6J mouse | Down |
| Study M956 | Type2 | CUMS + deoiled sunflower seeds group vs. CUMS group | Faece | C57BL/6J mouse | Up |
| Study M956 | Type2 | CUMS + whey protein-based group vs. CUMS group | Faece | C57BL/6J mouse | Up |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M985 | Type2 | CUMS + indole acetic acid group vs. CUMS group | Cecum | C57BL/6J mouse | Up |
| Study M999 | Type1 | CRS group vs. control group | Faece | C57BL/6J mouse | Down |
| Study M999 | Type2 | CRS + paroxetine group vs. CRS group | Faece | C57BL/6J mouse | Up |
| Study M999 | Type2 | CRS + high dose of neoagaro-oligosaccharides group vs. CRS group | Faece | C57BL/6J mouse | Up |